Patient outcome according to cytogenetic subgroups
. | . | CIF . | EFS . | OS . | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Cytogenetic subgroup . | Patients . | 5-y estimates (95% CI) . | SHR (95% CI) . | P . | 5-y estimates (95% CI) . | HR (95% CI) . | P . | 5-y estimates (95% CI) . | HR (95% CI) . | P . |
All patients | 542 | |||||||||
Primary subgroups† | N (%) | |||||||||
t(4;11)(q21;q23) | 72 (13) | 37.6% (28-50) | 1.13 (1.01-1.27) | .040 | 42.8% (31-54) | 1.12 (1.01-1.24) | .027 | 45.7% (34-57) | 1.17 (1.05-1.30) | .005 |
Other t(v;11q23) | 11 (2) | 18.2% (5-55) | 0.90 (0.68-1.20) | .48 | 63.6% (30-85) | 0.96 (0.79-1.18) | .73 | 72.7% (37-90) | 0.93 (0.74-1.18) | .57 |
t(1;19)(q23;p13) | 28 (5) | 28.6% (15-49) | 1.13 (0.91-1.40) | .28 | 53.6% (34-70) | 1.05 (0.86-1.29) | .63 | 57.1% (37-73) | 1.09 (0.88-1.35) | .43 |
Ho-Tr | 33 (6) | 36.4% (23-55) | 1.45 (0.79-2.64) | .23 | 35.8% (20-52) | 1.81 (1.10-2.98) | .020 | 38.6% (22-55) | 2.06 (1.21-3.51) | .007 |
HeH | 36 (7) | 22.9% (12-41) | 1.00 (0.71-1.40) | .99 | 63.0% (45-77) | 0.88 (0.65-1.20) | .42 | 72.0% (54-84) | 0.93 (0.68-1.28) | .67 |
ETV6-RUNX1 | 2 (0.3) | — | NT | — | — | NT | — | — | NT | — |
iAMP21 | 3 (0.5) | — | NT | — | — | NT | — | — | NT | — |
14q32/IGH | 27 (5) | 41.2% (25-62) | 1.06 (0.98-1.15) | .12 | 19.7% (7-37) | 1.13 (1.06-1.20) | <.001 | 30.6% (14-49) | 1.13 (1.06-1.21) | <.001 |
Other abnormalities | 210 (39) | 31.8% (26-37) | 1.02 (0.98-1.06) | .28 | 48.2% (41-55) | 1.02 (0.99-1.06) | .16 | 53.0% (46-60) | 1.03 (0.99-1.07) | .07 |
No identified abnormalities | 120 (22) | 22.6% (16-31) | Control | — | 60.3% (51-69) | Control | — | 63.2% (54-71) | Control | — |
Secondary abnormalities‡ | N/N evaluable (%) | |||||||||
del(6q) | 23/492 (5) | — | 0.96 (0.47-1.95) | .91 | — | 0.82 (0.44-1.55) | .55 | — | 0.94 (0.50-1.77) | .84 |
del(7p) | 29/494 (6) | — | 0.84 (0.43-1.64) | .60 | — | 0.89 (0.51-1.56) | .69 | — | 1.02 (0.58-1.79) | .94 |
Monosomy 7 | 53/510 (10) | — | 1.00 (0.63-1.57) | .99 | — | 1.18 (0.81-1.73) | .39 | — | 1.23 (0.82-1.83) | .32 |
del(9p) | 67/493 (14) | — | 1.10 (0.73-1.66) | .65 | — | 1.05 (0.74-1.51) | .78 | — | 0.86 (0.57-1.28) | .46 |
Monosomy 9 | 39/511 (8) | — | 1.07 (0.65-1.76) | .80 | — | 1.48 (0.99-2.23) | .056 | — | 1.62 (1.06-2.47) | .026 |
del(13q) | 15/494 (3) | — | 0.51 (0.16-1.60) | .25 | — | 0.53 (0.22-1.29) | .17 | — | 0.50 (0.18-1.34) | .17 |
Monosomy 13 | 32/506 (6) | — | 0.99 (0.56-1.74) | .97 | — | 1.38 (0.87-2.18) | .16 | — | 1.55 (0.97-2.48) | .07 |
del(17p) | 11/493 (2) | — | 1.98 (0.88-4.47) | .10 | — | 1.71 (0.81-3.63) | .16 | — | 1.79 (0;84-3.81) | .13 |
Monosomy 17 | 36/508 (7) | — | 1.01 (0.60-1.69) | .97 | — | 1.53 (0.01-2.31) | .043 | — | 1.69 (1.10-2.61) | .016 |
Complex karyotype | 27/527 (5) | 18.5% (8-39) | 0.53 (0.24-1.20) | .13 | 59.0% (38-75) | 0.72 (0.39-1.31) | .28 | 62.7% (42-78) | 0.74 (0.39-1.39) | .35 |
Monosomal karyotype | 82/518 (16) | 33.3% (24-45) | 1.22 (0.85-1.75) | .27 | 40.4% (30-51) | 1.36 (0.996-1.85) | .053 | 45.7% (35-56) | 1.38 (0.995-1.92) | .054 |
. | . | CIF . | EFS . | OS . | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Cytogenetic subgroup . | Patients . | 5-y estimates (95% CI) . | SHR (95% CI) . | P . | 5-y estimates (95% CI) . | HR (95% CI) . | P . | 5-y estimates (95% CI) . | HR (95% CI) . | P . |
All patients | 542 | |||||||||
Primary subgroups† | N (%) | |||||||||
t(4;11)(q21;q23) | 72 (13) | 37.6% (28-50) | 1.13 (1.01-1.27) | .040 | 42.8% (31-54) | 1.12 (1.01-1.24) | .027 | 45.7% (34-57) | 1.17 (1.05-1.30) | .005 |
Other t(v;11q23) | 11 (2) | 18.2% (5-55) | 0.90 (0.68-1.20) | .48 | 63.6% (30-85) | 0.96 (0.79-1.18) | .73 | 72.7% (37-90) | 0.93 (0.74-1.18) | .57 |
t(1;19)(q23;p13) | 28 (5) | 28.6% (15-49) | 1.13 (0.91-1.40) | .28 | 53.6% (34-70) | 1.05 (0.86-1.29) | .63 | 57.1% (37-73) | 1.09 (0.88-1.35) | .43 |
Ho-Tr | 33 (6) | 36.4% (23-55) | 1.45 (0.79-2.64) | .23 | 35.8% (20-52) | 1.81 (1.10-2.98) | .020 | 38.6% (22-55) | 2.06 (1.21-3.51) | .007 |
HeH | 36 (7) | 22.9% (12-41) | 1.00 (0.71-1.40) | .99 | 63.0% (45-77) | 0.88 (0.65-1.20) | .42 | 72.0% (54-84) | 0.93 (0.68-1.28) | .67 |
ETV6-RUNX1 | 2 (0.3) | — | NT | — | — | NT | — | — | NT | — |
iAMP21 | 3 (0.5) | — | NT | — | — | NT | — | — | NT | — |
14q32/IGH | 27 (5) | 41.2% (25-62) | 1.06 (0.98-1.15) | .12 | 19.7% (7-37) | 1.13 (1.06-1.20) | <.001 | 30.6% (14-49) | 1.13 (1.06-1.21) | <.001 |
Other abnormalities | 210 (39) | 31.8% (26-37) | 1.02 (0.98-1.06) | .28 | 48.2% (41-55) | 1.02 (0.99-1.06) | .16 | 53.0% (46-60) | 1.03 (0.99-1.07) | .07 |
No identified abnormalities | 120 (22) | 22.6% (16-31) | Control | — | 60.3% (51-69) | Control | — | 63.2% (54-71) | Control | — |
Secondary abnormalities‡ | N/N evaluable (%) | |||||||||
del(6q) | 23/492 (5) | — | 0.96 (0.47-1.95) | .91 | — | 0.82 (0.44-1.55) | .55 | — | 0.94 (0.50-1.77) | .84 |
del(7p) | 29/494 (6) | — | 0.84 (0.43-1.64) | .60 | — | 0.89 (0.51-1.56) | .69 | — | 1.02 (0.58-1.79) | .94 |
Monosomy 7 | 53/510 (10) | — | 1.00 (0.63-1.57) | .99 | — | 1.18 (0.81-1.73) | .39 | — | 1.23 (0.82-1.83) | .32 |
del(9p) | 67/493 (14) | — | 1.10 (0.73-1.66) | .65 | — | 1.05 (0.74-1.51) | .78 | — | 0.86 (0.57-1.28) | .46 |
Monosomy 9 | 39/511 (8) | — | 1.07 (0.65-1.76) | .80 | — | 1.48 (0.99-2.23) | .056 | — | 1.62 (1.06-2.47) | .026 |
del(13q) | 15/494 (3) | — | 0.51 (0.16-1.60) | .25 | — | 0.53 (0.22-1.29) | .17 | — | 0.50 (0.18-1.34) | .17 |
Monosomy 13 | 32/506 (6) | — | 0.99 (0.56-1.74) | .97 | — | 1.38 (0.87-2.18) | .16 | — | 1.55 (0.97-2.48) | .07 |
del(17p) | 11/493 (2) | — | 1.98 (0.88-4.47) | .10 | — | 1.71 (0.81-3.63) | .16 | — | 1.79 (0;84-3.81) | .13 |
Monosomy 17 | 36/508 (7) | — | 1.01 (0.60-1.69) | .97 | — | 1.53 (0.01-2.31) | .043 | — | 1.69 (1.10-2.61) | .016 |
Complex karyotype | 27/527 (5) | 18.5% (8-39) | 0.53 (0.24-1.20) | .13 | 59.0% (38-75) | 0.72 (0.39-1.31) | .28 | 62.7% (42-78) | 0.74 (0.39-1.39) | .35 |
Monosomal karyotype | 82/518 (16) | 33.3% (24-45) | 1.22 (0.85-1.75) | .27 | 40.4% (30-51) | 1.36 (0.996-1.85) | .053 | 45.7% (35-56) | 1.38 (0.995-1.92) | .054 |